discussed

BREATHE! Appreciation & Mixer Ignites Excitement, Setting the Stage for Global Tech Revolution

Source Node:
Time Stamp: June 9, 2023 6:05 AM - Modified On: June 9, 2023 - Published By:
Source Cluster:
Republished By Plato

For Immediate Release June 8, 2023 LAS VEGAS, NV - BREATHE! Convention, BREATHE! Appreciation & Mixer event, which took place from May 3rd - 5th, 2023, at the Renaissance Hotel in Las Vegas, was met with an overwhelmingly positive reception as more than one hundred pioneers and emerging tech leaders shook hands, exchanged ideas, and built business relationships in anticipation for the upcoming BREATHE! Convention. Within attendance of this 3-day networking event included Web3 artists, blockchain developers and startups, venture capitalists, and other business leaders transforming the space of Web3,

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Travelzoo META Opens for Founding Members

Source Node:
Time Stamp: May 11, 2023 7:21 AM - Modified On: May 11, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK/PARIS/TOKYO, May 11, 2023 - (ACN Newswire) - The future of travel is here. After months of anticipation, Travelzoo META, a members-only service offering groundbreaking Metaverse travel experiences, is now accepting its first one million Founding Members. Launched by Travelzoo® (NASDAQ: TZOO), a global Internet media company, Travelzoo META will give Founding Members the opportunity to be the first to experience travel in the Metaverse. Travelzoo META's experiences are intended to allow its members to explore hard-to-reach corners of the world, like summiting Mount Everest, or travel back in time—to

Verseon Acquires Edammo to Deepen Drug Discovery Approach

Source Node:
Time Stamp: November 13, 2022 3:46 AM - Modified On: November 17, 2022 - Published By:
Source Cluster:
Republished By Plato

Published: Nov 12th, 2022 | By Mark Terry Verseon Corporation has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform, the companies revealed Tuesday. Adityo Prakash, co-founder and CEO of Verseon and Ed Ratner, CEO at Edammo, discussed the acquisition with BioSpace. “We develop completely new drugs on the computer, atom by atom, then we make them in the laboratory,” Prakash said. "We’re changing how small molecule drugs are designed and developed with a level of efficiency that hasn’t been possible before.” He added that

The Government Blockchain Association (GBA)’s EMEA Lead to speak at UK House of Commons

Source Node:
Time Stamp: October 19, 2022 2:24 AM - Modified On: October 19, 2022 - Published By:
Source Cluster:
Republished By Plato

Wednesday 19th October 2022 from 17:30-19:00 (BST), theAll-Party Parliamentary Group (APPG) on Blockchain Chair in the House of Commons, Martin Docherty-Hughes MP, has invited Ms. Priya Guliani, (the Government Blockchain Association’s Regional Lead for Europe, Middle East, and Africa), to speak at the APPG Evidence Meeting on Sustainability & Climate Change: Energy Consumption & Other Issues. This meeting is part of the APPG’s work on blockchain in the UK Parliament, and part of a series of APPG meetings to make the policymakers aware of blockchain technology's developments, applications, and regulatory implications.